Study | Disease | Therapy | n | Lesion size | Dosimetry method | Endpoint | Threshold |
---|---|---|---|---|---|---|---|
Maxon (139) | Thyroid cancer metastases | 131I radioiodine | 76 | Planar conjugate views | Response on 131I planar scans | 80 Gy for metastases; 300 Gy for remnants | |
Wierts (140) | Thyroid cancer remnants and metastases | 131I radioiodine | 47 | >0.15 cm3 | 124I PET + OLINDA sphere model | CR on 131I SPECT or 124I PET | 40 Gy for metastases; 90 Gy for remnants |
Pauwels (102) | NET | 90Y-DOTATOC PRRT | 13 | NA | 86Y-DOTATOC PET + MIRDOSE sphere model | Volume shrinkage > 30% on CT | ∼150 Gy for >30% shrinkage |
Ilan (103) | NET | 177Lu-DOTATATE PRRT | 24 (24 tumors) | >2.2 cm | SPECT/CT + OLINDA sphere model | RECIST best response > 30% | ∼150 Gy |
Matthay (141) | Neuroblastoma | 131I-metaiodobenzylguanidine | 27 | Planar conjugate view + MIRDOSE | Volume shrinkage > 50% on CT | 70 Gy | |
Dewaraja (16) | Non-Hodgkin lymphoma | 131I-radioimmunotherapy | 39 (130 tumors) | Median, 20 cm3 | Multi-SPECT/CT + Monte Carlo | Progression-free survival | 200 cGy |
CR = complete response.